New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: New obesity drugs are coming, including the 'triple agonist' Retatrutide (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and glucagon In a trial, Retatrutide caused loss of ~25% of bodyweight (in patients with obesity) in less than a year: 25% in a year might be a little fast
Sciatica symptoms can appear anywhere along the nerves route when illness is present
They include carbidopa/levodopa (Sinemet), pramipexole (Mirapex), ropinirole (Requip) and the rotigotine patch (Neupro)
By addressing these directions, research can offer reliable, evidence-based insights, thereby advancing the clinical application of acupuncture in treating TBI
Theres also the not-so-quiet rise of fiber
Final Thoughts Semaglutide and tirzepatide both regulate appetite and blood sugar, but their distinct receptor mechanisms may lead to different outcomes based on individual health goals
